Discover
ASND
Ascendis Pharma A/S
229.27
1 x 228.43
1 x 228.83
bid
ask
+
4.27
1.90%
1 @ 04:00 PM
232.75 +3.48 (1.52%)
| Ytd | 7.52% | |
| 1y | 42.89% |
222.02
day range
229.58
151.25
52 week range
249.84
| Open | 224.21 | Prev Close | 225.00 | Low | 222.02 | High | 229.58 | Mkt Cap | 14.16B |
| Vol | 590.84K | Avg Vol | 663.86K | EPS | -4.49 | P/E | N/A | Forward P/E | 24.90 |
| Beta | 0.48 | Short Ratio | 6.47 | Inst. Own | 108.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 230.90 | 200-d Avg | 208.77 | 1yr Est | 339.24 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0.21 | N/A | N/A | N/A |
| 2026-02-11 | 2025-12 | 0 | N/A | -0.58 | -966.67% |
| 2025-11-12 | 2025-09 | 0 | N/A | -0.76 | -185.37% |
| 2025-08-07 | 2025-06 | 0 | N/A | 0.49 | 34.51% |
| 2025-05-01 | 2025-03 | 0 | N/A | -0.1 | -6.41% |
| 2025-02-12 | 2024-12 | 0 | N/A | 0.52 | 43.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-16 | B of A Securities | Upgrade | Buy | Buy |
| 2026-04-09 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-03-03 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-02-12 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2026-02-12 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-01-30 | B of A Securities | Upgrade | Buy | Buy |
Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | RA Capital Management, L.P. | 10.28M | 2.36B | 16.48% |
| 2025-12-30 | Westfield Capital Management Co LP | 5.19M | 1.19B | 8.31% |
| 2025-12-30 | Avoro Capital Advisors LLC | 5.11M | 1.17B | 8.19% |
| 2025-12-30 | FMR, LLC | 4.15M | 952.23M | 6.66% |
| 2025-12-30 | Janus Henderson Group PLC | 4.06M | 931.21M | 6.51% |
| 2025-12-30 | Artisan Partners Limited Partnership | 3.23M | 739.60M | 5.17% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-11-29 | MFS Series Trust IV-MFS Mid Cap Growth Fund | 1.28M | 293.41M | 2.05% |
| 2025-12-30 | GROWTH FUND OF AMERICA | 1.21M | 277.34M | 1.94% |
| 2026-01-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.10M | 252.99M | 1.77% |
| 2025-12-30 | Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 1000.00K | 229.27M | 1.60% |
| 2025-12-30 | T. Rowe Price Mid-Cap Growth Fund, Inc. | 784.10K | 179.77M | 1.26% |
| 2025-12-30 | JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 731.87K | 167.80M | 1.17% |
